Key Takeaways
- • Private equity deal value in life sciences declined in 2023 relative to 2022 levels, despite continued sector attractiveness, as economic uncertainty and elevated interest rates pressured overall buyout activity across biopharma, diagnostics, and life-sciences tools verticals.
- • Pharma services—including contract research organizations (CROs) and contract development manufacturing organizations (CDMOs)—outperformed broader life sciences deal activity, with deal values exceeding 2022 levels, signaling PE investor preference for defensive, service-oriented businesses.
- • Biotech funding headwinds persisted in 2023, yet investor appetite for early-stage therapies and precommercial medical devices showed signs of recovery, indicating a gradual thaw in venture and growth-stage financing conditions.
- • The Inflation Reduction Act's drug negotiation provisions and accelerating investment in cell, gene, and RNA therapies will create operational and commercial ripple effects across service providers and supply chain participants in the life sciences ecosystem.
- • Surging demand for glucagon-like peptide-1 agonists (GLP-1s)—including Wegovy, Ozempic, Mounjaro, and Zepbound—is driving incremental demand for manufacturing ingredients and specialized services, creating new investment opportunities in ancillary supply chain assets.
Summary
The life sciences sector maintained its appeal to private equity investors in 2023 despite a challenging macroeconomic backdrop, though overall deal activity contracted year-over-year. According to Bain's 2024 Global Healthcare Private Equity Report, private equity deal value in life sciences struggled to match 2022 performance as economic uncertainty and persistent high interest rates weighed on buyout valuations and financing availability. From 2018 through 2022, the sector had generated approximately 650 global buyout deals across biopharma, life-sciences tools, and diagnostics, establishing life sciences as a core alternative-asset class for PE funds pursuing innovative, recession-resistant investment targets.
Within this contracting landscape, pharma services emerged as a relative outperformer. Contract research organizations (CROs) and contract development manufacturing organizations (CDMOs) demonstrated resilience, with deal values surpassing 2022 levels. This outperformance reflects PE investors' increasing preference for de-risked, cash-generative service businesses over higher-risk drug development assets, particularly as financing conditions tightened. The shift suggests a tactical reorientation toward businesses with predictable revenue streams and established customer relationships rather than early-stage innovation bets.
Concurrent with these trends, early signs of recovery emerged in venture and growth-stage financing. Despite the ongoing biotech funding slowdown, investors displayed measurable comfort deploying capital into early-stage therapies and precommercial medical devices, suggesting selective capital flow returning to emerging innovation ecosystems. This bifurcation—weakness in traditional buyouts offset by selective early-stage appetite—reflects sophisticated investor discrimination in response to cost-of-capital dynamics.
Regulatory and commercial shifts are reshaping the investment opportunity set. The Inflation Reduction Act's drug negotiation provisions will cascade through pharma services and supply chain participants, requiring operational adaptation. Simultaneously, heightened investment in cell, gene, and RNA therapies is reconfiguring capital allocation patterns and creating specialized expertise demands. Most tangibly, explosive demand for GLP-1 agonists—led by Wegovy, Ozempic, Mounjaro, and Zepbound—is creating ancillary investment opportunities in manufacturing ingredients, specialized services, and supply-chain logistics. PE success in life sciences now requires integrated capabilities spanning scientific proficiency, operational excellence, and commercial acumen to navigate these structural shifts.
Within this contracting landscape, pharma services emerged as a relative outperformer. Contract research organizations (CROs) and contract development manufacturing organizations (CDMOs) demonstrated resilience, with deal values surpassing 2022 levels. This outperformance reflects PE investors' increasing preference for de-risked, cash-generative service businesses over higher-risk drug development assets, particularly as financing conditions tightened. The shift suggests a tactical reorientation toward businesses with predictable revenue streams and established customer relationships rather than early-stage innovation bets.
Concurrent with these trends, early signs of recovery emerged in venture and growth-stage financing. Despite the ongoing biotech funding slowdown, investors displayed measurable comfort deploying capital into early-stage therapies and precommercial medical devices, suggesting selective capital flow returning to emerging innovation ecosystems. This bifurcation—weakness in traditional buyouts offset by selective early-stage appetite—reflects sophisticated investor discrimination in response to cost-of-capital dynamics.
Regulatory and commercial shifts are reshaping the investment opportunity set. The Inflation Reduction Act's drug negotiation provisions will cascade through pharma services and supply chain participants, requiring operational adaptation. Simultaneously, heightened investment in cell, gene, and RNA therapies is reconfiguring capital allocation patterns and creating specialized expertise demands. Most tangibly, explosive demand for GLP-1 agonists—led by Wegovy, Ozempic, Mounjaro, and Zepbound—is creating ancillary investment opportunities in manufacturing ingredients, specialized services, and supply-chain logistics. PE success in life sciences now requires integrated capabilities spanning scientific proficiency, operational excellence, and commercial acumen to navigate these structural shifts.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.